R&D expenses and the number of employees at privately held biotech companies - mostly start-ups - have reached new record levels. Investments have also recovered. However, the market is divided into successful high flyers and biotechs that are struggling. This gap is even wider for public companies, as the Swiss Biotech Report 2024 shows..

私营生物技术公司（主要是初创公司）的研发费用和员工人数达到了创纪录的水平。投资也有所恢复。然而，该市场分为成功的高人和苦苦挣扎的生物技术。正如《2024年瑞士生物技术报告》所示，上市公司的这一差距甚至更大。。

The overall picture of the Swiss biotech industry in the Swiss Biotech Report published today is quite positive. In addition to record revenues of CHF 7.3 billion, the industry raised more than CHF 2 billion – a remarkable 50% increase over 2022. This comprised around CHF 1.4 billion collected by public companies, and the remaining CHF 0.6 billion by private companies.

今天发表的瑞士生物技术报告中，瑞士生物技术行业的总体情况相当乐观。除了创纪录的73亿瑞士法郎的收入外，该行业还筹集了20多亿瑞士法郎，比2022年显著增加了50%。其中包括上市公司筹集的约14亿瑞士法郎，其余6亿瑞士法郎由私营公司筹集。

Although R&D investments dipped slightly to CHF 2.4 billion, they are still at very high levels. The latest edition of the Swiss Biotech Report launched today by the Swiss Biotech Association, in conjunction with EY and eight other partner organizations, provides an analysis of the 2023 biotech funding as well as other 2023 key ratios and statistics..

尽管研发投资略微下降至24亿瑞士法郎，但仍处于非常高的水平。瑞士生物技术协会（Swiss Biotech Association）今天与安永（EY）和其他八个合作伙伴组织共同发布了最新版本的《瑞士生物技术报告》，该报告对2023年生物技术资金以及其他2023年关键比率和统计数据进行了分析。。

The positive impression is due to the good performance of the industry's high flyers. 'There is a clear difference between the haves and have-nots,' was the message at the presentation of the report. It is also noticeable that privately held biotech companies - generally start-ups - perform more robustly than listed companies.

给人留下积极印象的原因是该行业的成功人士表现良好。”报告中的信息是，富人和穷人之间有着明显的区别。同样值得注意的是，私营生物技术公司（通常是初创公司）比上市公司表现更为强劲。

In 2023, private biotech companies increased the number of employees to almost 8,000 and R&D expenses to CHF 1.15 billion. Growth was driven by increasing investments. According to the methodology of the Biotech Report, which also includes debt financing and strategic investments, private biotech companies received CHF 643 million..

2023年，私营生物技术公司将员工人数增加到近8000人，研发费用增加到11.5亿瑞士法郎。增长是由不断增加的投资推动的。根据生物技术报告的方法，其中还包括债务融资和战略投资，私营生物技术公司收到了6.43亿瑞士法郎。。

In the area of public companies, investments rose even more sharply - to CHF 1.4 billion - but at the same time the number of employees and R&D expenditure fell. Only the industry's high flyers benefited from the large investments, while others were unable to raise as much money as they had planned and therefore had to reduce their expenditure and headcount..

在上市公司领域，投资增长更为迅猛，达到14亿瑞士法郎，但与此同时，员工人数和研发支出却下降了。只有该行业的高层人才从巨额投资中受益，而其他人无法筹集到他们计划的那么多资金，因此不得不减少支出和人数。。

Top 5 fundings in 2023

2023年前五大基金

On the other hand, the Swiss biotech industry generated record revenues of CHF 7.3 billion compared to CHF 6.8 billion in 2022. This was driven by significant collaboration and licensing deals of public companies, which often successfully partner with large pharma companies, and product sales boosted by a record number of approvals from Swissmedic, EMA, FDA and other global regulatory authorities, including breakthrough advanced therapies from CRISPR Therapeutics, Santhera Pharmaceuticals, Idorsia, Relief Therapeutics and Basilea..

另一方面，瑞士生物技术行业创造了创纪录的73亿瑞士法郎的收入，而2022年的收入为68亿瑞士法郎。这是由上市公司的重大合作和许可协议所推动的，上市公司通常与大型制药公司成功合作，产品销售也受到Swissmedic，EMA，FDA和其他全球监管机构创纪录的批准数量的推动，包括CRISPR Therapeutics，Santhera Pharmaceuticals，Idorsia，Relief Therapeutics和Basilea的突破性高级疗法。。

The report contains other indicators that also bode well for the future. For example, the number of biotech companies increased further to 308. In addition, the Swiss biotech sector has an excellently filled pipeline comprising 1200 drugs. More than 400 of these have already been licensed. The most important areas of application are oncology with 462 assets, neurology (180) and metabolic (153)..

该报告还包含其他指标，这些指标对未来也是一个好兆头。例如，生物技术公司的数量进一步增加到308家。此外，瑞士生物技术部门拥有一条由1200种药物组成的管道。其中400多个已经获得许可。最重要的应用领域是拥有462项资产的肿瘤学、神经学（180项）和代谢学（153项）。。

The international importance of the Swiss biotech sector is also impressively demonstrated by the Swiss Biotech Day, during which the Swiss Biotech Report was launched. The event attracted 2200 participants to Basel, over 1000 of whom travelled from abroad.

瑞士生物技术日（Swiss biotech Day）也令人印象深刻地证明了瑞士生物技术部门的国际重要性，瑞士生物技术报告就是在该日发布的。此次活动吸引了2200名参与者来到巴塞尔，其中1000多人来自国外。

0Comments

0注意事项

Back to all news

返回所有新闻

Please login

请登录

or sign up

或注册

to comment.

发表评论。

Commenting guidelines

评论指南

Send

发送